Younes Ahmad, Al-Kindi Sadeer G, Alajaji Wissam, Mackall Judith A, Oliveira Guilherme H
Advanced Heart Failure & Transplant Center and the Arrhythmia Center, Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Advanced Heart Failure & Transplant Center and the Arrhythmia Center, Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Int J Cardiol. 2017 Mar 15;231:211-215. doi: 10.1016/j.ijcard.2016.12.148. Epub 2016 Dec 28.
The role of implantable cardioverter defibrillator (ICD) in reducing mortality in patients with left ventricular assisted devices (LVADs) listed for heart transplant remains unclear. We therefore, sought to interrogate whether ICDs are associated with reduced mortality in patients with LVADs listed for heart transplantation.
We searched the United Network for Organ Sharing (UNOS) Registry for LVAD patients (age≥18years) with dilated cardiomyopathies listed for heart transplantation (2008-2015). The group was matched by propensity scores with respect to presence of ICD at listing. The primary end-point was waitlist mortality, while secondary endpoints were waitlist mortality, delisting, or cardiovascular cause-specific mortality in patients with and without ICD.
A total of 1444 LVAD patients were included in this analysis (722 with ICD, 722 without ICD). No statistically-significant differences were present between the two groups in demographics, device type, listing status, or hemodynamics. The presence of an ICD was not associated with decreased wait-list mortality (Hazard Ratio 1.19 [0.75-1.88], p=0.46), waitlist mortality/delisting (Hazard Ratio 1.20 [0.86-1.67], p=0.28), or cardiovascular wait-list mortality (HR 1.24 [0.45-3.43], p=0.67) over a median of 5.6months. Only 7 deaths occurred due to arrhythmia/cardiac arrest (2 in the ICD group and 5 in the non-ICD group).
Presence of ICDs at listing in heart failure patients bridged to transplantation with durable LVADs is not associated with lower waitlist mortality, cardiovascular wait-list mortality or wait-list mortality or delisting; however, there were numerically fewer arrhythmic deaths in the ICD group. Additional prospective studies should be undertaken to confirm these findings.
植入式心脏复律除颤器(ICD)在降低等待心脏移植的左心室辅助装置(LVAD)患者死亡率方面的作用仍不明确。因此,我们试图探究ICD是否与等待心脏移植的LVAD患者死亡率降低相关。
我们在器官共享联合网络(UNOS)登记处搜索了2008年至2015年期间因扩张型心肌病而等待心脏移植的LVAD患者(年龄≥18岁)。根据植入ICD时的倾向评分对该组进行匹配。主要终点是等待名单上的死亡率,次要终点是有或没有ICD的患者的等待名单上的死亡率、从等待名单上除名或心血管病因特异性死亡率。
本分析共纳入1444例LVAD患者(722例有ICD,722例无ICD)。两组在人口统计学、装置类型、登记状态或血流动力学方面无统计学显著差异。ICD的存在与等待名单死亡率降低(风险比1.19 [0.75 - 1.88],p = 0.46)、等待名单死亡率/除名率(风险比1.20 [0.86 - 1.67],p = 0.28)或心血管等待名单死亡率(HR 1.24 [0.45 - 3.43],p = 0.67)无关,中位随访时间为5.6个月。仅7例死亡是由于心律失常/心脏骤停(ICD组2例,非ICD组5例)。
在使用耐用LVAD过渡到移植的心力衰竭患者中,登记时存在ICD与较低的等待名单死亡率以及心血管等待名单死亡率或等待名单死亡率/除名率无关;然而,ICD组心律失常死亡人数在数值上较少。应进行更多前瞻性研究以证实这些发现。